DiscoveryProbe™ Bioactive Compound Library Plus: Atomic I...
2026-01-26
The DiscoveryProbe™ Bioactive Compound Library Plus (L1022P) is a rigorously validated bioactive compound library for high-throughput screening and mechanistic pathway analysis. This collection supports apoptosis assays, cancer research, and kinase inhibitor profiling with stable, cell-permeable compounds. It enables reproducible, data-rich investigation across multiple disease models.
EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP): Dual-Mode,...
2026-01-25
EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) is a Cap1-capped, 5-moUTP- and Cy5-labeled mRNA that enables robust mammalian translation and dual-mode detection. This product delivers enhanced stability, immune evasion, and precise reporter readouts, making it a benchmark tool for mRNA delivery and bioluminescence imaging.
Translating Mechanistic Insight into Innovation: XAV-939 ...
2026-01-24
This thought-leadership article explores the critical role of XAV-939, a potent tankyrase 1 and 2 inhibitor, in modulating the Wnt/β-catenin signaling pathway for translational researchers. Blending mechanistic detail with strategic application, the piece covers biological rationale, experimental validation, the competitive landscape, translational impact, and future perspectives—highlighting how XAV-939 from APExBIO advances the field beyond conventional applications.
Crizotinib Hydrochloride: Dissecting Stromal-Driven Drug ...
2026-01-24
Explore how Crizotinib hydrochloride, a leading ALK kinase inhibitor, unlocks advanced insights into stromal-driven drug resistance using next-generation assembloid models. This article uniquely focuses on the interplay between tumor and stromal cells, guiding cancer biology research beyond traditional approaches.
DMXAA (Vadimezan, AS-1404): Unraveling Endothelial Apopto...
2026-01-23
Explore how DMXAA (Vadimezan, AS-1404) advances cancer biology research as a potent vascular disrupting agent and DT-diaphorase inhibitor. This article uniquely delves into the intersection of endothelial apoptosis, VEGFR2 signaling, and STING-JAK1 modulation for next-generation tumor vasculature disruption.
Safe DNA Gel Stain: High-Sensitivity, Less Mutagenic Nucl...
2026-01-23
Safe DNA Gel Stain is a less mutagenic nucleic acid stain that enables sensitive detection of DNA and RNA in agarose and acrylamide gels, using blue-light or UV excitation. This ethidium bromide alternative from APExBIO reduces DNA damage, improves cloning efficiency, and supports biosafe molecular biology workflows.
Optimizing Cell-Based Assays: Scenario-Driven Solutions U...
2026-01-22
This evidence-based article addresses recurring laboratory challenges in cell viability, proliferation, and cytotoxicity assays, illustrating how Substance P (SKU B6620) offers reproducible, high-purity solutions for neurokinin-1 receptor research. Drawing from peer-reviewed literature and real-world laboratory scenarios, it guides biomedical researchers in experimental design, protocol optimization, and product selection for reliable pain transmission and neuroinflammation studies.
PD0325901: Precision MEK Inhibition Unlocks New Frontiers...
2026-01-22
Discover how PD0325901, a selective MEK inhibitor, drives breakthrough research in cancer and stem cell biology by precisely targeting the RAS/RAF/MEK/ERK signaling pathway. This article reveals unique mechanistic insights and advanced applications, setting a new benchmark beyond conventional protocol-focused reviews.
E-64: Transforming Cysteine Protease Inhibition from Mech...
2026-01-21
E-64, a potent L-trans-epoxysuccinyl peptide cysteine protease inhibitor, is redefining experimental rigor and translational capability in cell death, cancer, and signaling research. This article delivers a mechanistic deep-dive, strategic recommendations for translational researchers, and a future-looking perspective—integrating insights from high-impact studies and practical laboratory challenges.
Crizotinib Hydrochloride: ATP-Competitive ALK, c-Met, and...
2026-01-21
Crizotinib hydrochloride is a potent, ATP-competitive small molecule inhibitor targeting ALK, c-Met, and ROS1 kinases. It enables precise inhibition of oncogenic kinase signaling in advanced assembloid cancer models. This article details its mechanism, benchmarks, and integration into cancer biology research.
RG7388: Selective MDM2 Antagonist for p53 Pathway Activation
2026-01-20
RG7388 is a highly potent MDM2 antagonist that selectively activates the p53 pathway, leading to cancer cell apoptosis in wild-type p53 models. As a second-generation clinical inhibitor, RG7388 demonstrates superior potency over earlier compounds and shows efficacy in preclinical tumor models. This article details its mechanistic basis, benchmarks, and workflow parameters for translational oncology.
461 records 31/31 page Previous First page 上5页 31